Bill Taranto

at the time.

And today, Preventus is close to a billion dollar company.

It's one of the biggest successes for Boston Scientific today.

But it shows you how we use private equity to build a company by adding additional components and the gaps that we had.

Back to your first question, some of the different investments that we made that came out.

Probably one of the first ones we did that was pretty successful

was around solving a use case around diabetes management.

And we invested in a company called Livongo, which ended up IPO-ing for $3.5 billion and being sold to Teladoc for $18 billion.

Yeah, we did that with Glenn Tolman.

But that was one of the first big industry sort of use cases around a patient problem that we were trying to solve was how do you manage diabetes on a more global basis and have a fully integrated program where, again, much similar to Preventus.

In fact, what was sort of interesting was

We actually wanted to merge Labanga with Preventus at the time, but Glenn moved a little faster than we did.

They actually IPO before we sold Preventus because then you would have an entire metabolic company.

Imagine having cardiac and diabetes all in one company.

But nonetheless, we built that company in a similar fashion doing acquisitions as well along with Glenn.

And building that to a very successful today.

And what's interesting, it's actually a benefit for us as part of our Merck benefits.

If you're a diabetes patient, you have access then to Livongo as a company benefit.

And that company's just continued to do really well.

And that was kind of the first, I would say, patient use cases that we saw that was very successful when we switched over.